Roth MKM Reiterates Buy on Terns Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Dylan Dupuis has reiterated a 'Buy' rating on Terns Pharma (NASDAQ:TERN) and maintained a price target of $23.
August 08, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst has reiterated a 'Buy' rating on Terns Pharma and maintained a price target of $23.
The reiteration of a 'Buy' rating by a Roth MKM analyst and the maintenance of a $23 price target could potentially boost investor confidence in Terns Pharma, leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100